Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

Telangana fires up biologics innovation, debuts India's first single-use bioprocess scale-up hub

The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre

Thermo Fisher opens two new centers in Hyderabad

The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder

Eris Lifesciences consolidates its stake in Swiss Parenterals

The proposed transaction will be effected as a share swap

FDA investigates fatal case linked to rare blood disorder drug Adzynma

Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme

Bayer’s experimental stroke drug could reshape secondary stroke prevention

Millions of stroke survivors across the world may soon have a new defense

ACG unveils patent-clean laminate ‘DryPod’ to shake up moisture-protection market

The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules

AstraZeneca to invest $2 billion in Maryland manufacturing expansion

The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan